RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Alimera Sciences Stock

Alimera Sciences Employees 2024

Alimera Sciences Employees

122

Ticker

ALIM

ISIN

US0162592028

WKN

A2PVHE

In 2024, Alimera Sciences employed 122 people, a 0% change from the 122 number of employees in the previous year.

Alimera Sciences Aktienanalyse

What does Alimera Sciences do?

Alimera Sciences Inc. is a leading global company specializing in the development of pharmaceutical products for eye diseases. The company was founded in 2003 in Atlanta, Georgia, USA and has since made remarkable progress in developing innovative clinical solutions. Business model: Alimera Sciences Inc. strives to utilize the latest technologies and methods in ophthalmology to improve the quality of life for patients with eye diseases. The company works closely with leading research institutions to incorporate the latest scientific findings into its product development. Alimera Sciences has a wide range of research areas to develop innovative solutions for conditions such as diabetes-related macular degeneration, retinopathy, uveitis, and other eye diseases. The company also places great value on collaboration with the medical community and actively advocates for the improvement of patient care and the education of eye experts. Products: Alimera Sciences' products are specialized in the treatment of eye diseases and utilize various technologies to improve patients' quality of life. The flagship product of Alimera Sciences is Iluvien, an intravitreal implant for the treatment of chronic diabetic macular edema (DME). Iluvien is the only commercially available DME implant and offers a unique treatment option for patients who do not respond to standard treatments. In addition to Iluvien, Alimera Sciences also manufactures a range of other products, including Ozurdex, a steroid-containing intravitreal implant for the treatment of retinopathy and uveitis. Alimera Sciences also has an extensive portfolio of investigational drugs, many of which are in various stages of clinical development. History: Alimera Sciences was founded in 2003 by Daniel C. Myers and David R. Holland in Atlanta, Georgia. The company originally specialized in developing drugs for the treatment of lung diseases, but over the years, its focus shifted to ophthalmology. In 2011, the company received FDA approval for Iluvien, which was a significant milestone in the history of Alimera Sciences. Since then, the company has continuously expanded its presence in ophthalmology by increasing its research and development efforts and forming partnerships with key medical organizations and institutions. Today, Alimera Sciences is a leading provider of pharmaceutical solutions for eye diseases, focusing on the development of drugs to improve patients' quality of life and enhance medical care. Conclusion: Overall, Alimera Sciences is an innovative company specializing in the development of drugs for the treatment of eye diseases. In its 18 years of existence, the company has achieved an impressive success story and continues its efforts to attain a leading position in the ophthalmic industry. With insights and experience in medical history and the knowledge of important medical professionals, the company is prepared to continuously meet the medical needs and expectations of patients with eye diseases. Alimera Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Alimera Sciences's Employee Base

Alimera Sciences's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Alimera Sciences's operational capacity and future potential.

Year-to-Year Comparison

Assessing Alimera Sciences's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Alimera Sciences's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Alimera Sciences’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Alimera Sciences stock

How many employees does Alimera Sciences have this year?

Alimera Sciences has 122 undefined employees this year.

How many employees did Alimera Sciences have compared to the previous year?

Compared to the previous year, Alimera Sciences had 0% more employees.

What impact did the number of employees have on the company Alimera Sciences?

The number of employees has a direct impact on the efficiency and productivity of Alimera Sciences. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Alimera Sciences?

The number of employees can also have an impact on investors of Alimera Sciences, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Alimera Sciences affect the company?

An increase in equity of Alimera Sciences can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Alimera Sciences's equity affect the company?

A reduction in equity of Alimera Sciences can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Alimera Sciences?

Some factors that can influence the equity of Alimera Sciences include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Alimera Sciences so important for investors?

The equity of Alimera Sciences is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Alimera Sciences influence the company?

The number of employees at Alimera Sciences can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Alimera Sciences evolved in recent years?

In recent years, the number of employees at Alimera Sciences has changed by 0.

How many employees does Alimera Sciences currently have?

Alimera Sciences currently has 122 undefined employees.

Why is the number of employees important for investors of Alimera Sciences?

The number of employees is important for investors of Alimera Sciences as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Alimera Sciences take to change the number of employees?

To change the number of employees, Alimera Sciences can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Alimera Sciences pay?

Over the past 12 months, Alimera Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Alimera Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Alimera Sciences?

The current dividend yield of Alimera Sciences is .

When does Alimera Sciences pay dividends?

Alimera Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Alimera Sciences?

Alimera Sciences paid dividends every year for the past 0 years.

What is the dividend of Alimera Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Alimera Sciences located?

Alimera Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Alimera Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Alimera Sciences from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Alimera Sciences pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Alimera Sciences in the year 2023?

In the year 2023, Alimera Sciences distributed 0 USD as dividends.

In which currency does Alimera Sciences pay out the dividend?

The dividends of Alimera Sciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Alimera Sciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Alimera Sciences

Our stock analysis for Alimera Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alimera Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.